Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 9/20 | 0.59 |
| ▸ | GHSR | Q92847 | 4/20 | 0.50 |
| ▸ | NPY2R | P49146 | 3/20 | 0.50 |
| ▸ | MC5R | P33032 | 1/20 | 0.49 |
| ▸ | MC3R | P41968 | 1/20 | 0.49 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188828 | 0.92 | MC4R (0.68) | MC4RGHSRNPY2RMC5RMC3R | |
| SCHEMBL13035278 | 0.89 | MC4R (0.68) | MC4RGHSRNPY2RMC5RMC3R | |
| SCHEMBL29357687 | 0.82 | KISS1R (0.62) | MC4RMC5RMC3RMC1R | |
| SCHEMBL1449964 | 0.81 | IL23R (0.56) | MC4RMC1RIL23R | |
| SCHEMBL306027 | 0.81 | IL23R (0.56) | MC4RMC1RIL23R | |
| SCHEMBL14511692 | 0.79 | MC4R (0.71) | MC4RGHSRNPY2RIL23R | |
| SCHEMBL25767621 | 0.78 | MC4R (0.66) | MC4RGHSRMC5RMC3RMC1R | |
| SCHEMBL28714609 | 0.78 | IL23R (0.56) | MC4RMC1RIL23R | |
| SCHEMBL14511696 | 0.77 | MC4R (0.67) | MC4RGHSRNPY2RIL23R | |
| SCHEMBL23483109 | 0.76 | MC4R (0.71) | MC4RGHSRIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | MC4R 2878/4885GHSR 4049/4885NPY2R 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.